Oncotelic and Sapu Nano to Present Deciparticle Nanomedicine Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that CEO Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics, addressing a key challenge in drug delivery.

The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. Additionally, the presentation will highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform.

This announcement underscores the growing importance of nanomedicine in improving drug delivery and therapeutic index. The ability to intravenously administer drugs that are otherwise poorly soluble could expand treatment options for patients and reduce side effects associated with current formulations. For Oncotelic, which focuses on high-unmet-need cancers and rare pediatric indications, the Deciparticle platform represents a potential pipeline enhancer. The company also benefits from a robust portfolio of inventions by Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.

Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes. Beyond internal programs, the company licenses and co-develops drug candidates through strategic partnerships and holds a 45% interest in GMP Bio, a joint venture advancing complementary therapeutic candidates. For more details, the full press release is available at https://ibn.fm/RUG7m. The latest news and updates on OTLC can be found at https://ibn.fm/OTLC.

The BIO International Convention is a major industry event, and the presentation of Deciparticle technology could attract interest from potential partners and investors. As the company moves Sapu006 and Sapu003 into clinical trials, successful development could validate the platform's potential to unlock new clinical applications for established therapeutics. The use of AI in formulation development also positions Oncotelic at the forefront of digital transformation in drug discovery.